790 related articles for article (PubMed ID: 9804689)
1. Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.
Lingham RB; Silverman KC; Jayasuriya H; Kim BM; Amo SE; Wilson FR; Rew DJ; Schaber MD; Bergstrom JD; Koblan KS; Graham SL; Kohl NE; Gibbs JB; Singh SB
J Med Chem; 1998 Nov; 41(23):4492-501. PubMed ID: 9804689
[TBL] [Abstract][Full Text] [Related]
2. Clavaric acid: a triterpenoid inhibitor of farnesyl-protein transferase from Clavariadelphus truncatus.
Jayasuriya H; Silverman KC; Zink DL; Jenkins RG; Sanchez M; Pelaez F; Vilella D; Lingham RB; Singh SB
J Nat Prod; 1998 Dec; 61(12):1568-70. PubMed ID: 9868169
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
4. Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase.
Anthony NJ; Gomez RP; Schaber MD; Mosser SD; Hamilton KA; O'Neil TJ; Koblan KS; Graham SL; Hartman GD; Shah D; Rands E; Kohl NE; Gibbs JB; Oliff AI
J Med Chem; 1999 Aug; 42(17):3356-68. PubMed ID: 10464022
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of farnesyl protein transferase by monoterpene, curcumin derivatives and gallotannin.
Chen X; Hasuma T; Yano Y; Yoshimata T; Morishima Y; Wang Y; Otani S
Anticancer Res; 1997; 17(4A):2555-64. PubMed ID: 9252680
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.
Flint OP; Masters BA; Gregg RE; Durham SK
Toxicol Appl Pharmacol; 1997 Jul; 145(1):91-8. PubMed ID: 9221828
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4- (8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene )- piperidine inhibitors of farnesyl-protein transferase: design and synthesis of in vivo active antitumor compounds.
Njoroge FG; Vibulbhan B; Rane DF; Bishop WR; Petrin J; Patton R; Bryant MS; Chen KJ; Nomeir AA; Lin CC; Liu M; King I; Chen J; Lee S; Yaremko B; Dell J; Lipari P; Malkowski M; Li Z; Catino J; Doll RJ; Girijavallabhan V; Ganguly AK
J Med Chem; 1997 Dec; 40(26):4290-301. PubMed ID: 9435898
[TBL] [Abstract][Full Text] [Related]
8. Oreganic acid, a potent inhibitor of ras farnesyl-protein transferase.
Silverman KC; Jayasuriya H; Cascales C; Vilella D; Bills GF; Jenkins RG; Singh SB; Lingham RB
Biochem Biophys Res Commun; 1997 Mar; 232(2):478-81. PubMed ID: 9125205
[TBL] [Abstract][Full Text] [Related]
9. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.
Amin D; Rutledge RZ; Needle SN; Galczenski HF; Neuenschwander K; Scotese AC; Maguire MP; Bush RC; Hele DJ; Bilder GE; Perrone MH
J Pharmacol Exp Ther; 1997 May; 281(2):746-52. PubMed ID: 9152381
[TBL] [Abstract][Full Text] [Related]
10. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
Omer CA; Chen Z; Diehl RE; Conner MW; Chen HY; Trumbauer ME; Gopal-Truter S; Seeburger G; Bhimnathwala H; Abrams MT; Davide JP; Ellis MS; Gibbs JB; Greenberg I; Koblan KS; Kral AM; Liu D; Lobell RB; Miller PJ; Mosser SD; O'Neill TJ; Rands E; Schaber MD; Senderak ET; Oliff A; Kohl NE
Cancer Res; 2000 May; 60(10):2680-8. PubMed ID: 10825141
[TBL] [Abstract][Full Text] [Related]
11. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.
Leftheris K; Kline T; Vite GD; Cho YH; Bhide RS; Patel DV; Patel MM; Schmidt RJ; Weller HN; Andahazy ML; Carboni JM; Gullo-Brown JL; Lee FY; Ricca C; Rose WC; Yan N; Barbacid M; Hunt JT; Meyers CA; Seizinger BR; Zahler R; Manne V
J Med Chem; 1996 Jan; 39(1):224-36. PubMed ID: 8568812
[TBL] [Abstract][Full Text] [Related]
12. Regulation of proliferation and Ras localization in transformed cells by products of mevalonate metabolism.
Cuthbert JA; Lipsky PE
Cancer Res; 1997 Aug; 57(16):3498-505. PubMed ID: 9270019
[TBL] [Abstract][Full Text] [Related]
13. Photoaffinity labeling of yeast farnesyl protein transferase and enzymatic synthesis of a Ras protein incorporating a photoactive isoprenoid.
Edelstein RL; Distefano MD
Biochem Biophys Res Commun; 1997 Jun; 235(2):377-82. PubMed ID: 9199201
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells.
Bouterfa HL; Sattelmeyer V; Czub S; Vordermark D; Roosen K; Tonn JC
Anticancer Res; 2000; 20(4):2761-71. PubMed ID: 10953355
[TBL] [Abstract][Full Text] [Related]
15. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
Staal A; Frith JC; French MH; Swartz J; Güngör T; Harrity TW; Tamasi J; Rogers MJ; Feyen JH
J Bone Miner Res; 2003 Jan; 18(1):88-96. PubMed ID: 12510809
[TBL] [Abstract][Full Text] [Related]
16. C-terminal modifications of histidyl-N-benzylglycinamides to give improved inhibition of Ras farnesyltransferase, cellular activity, and anticancer activity in mice.
McNamara DJ; Dobrusin E; Leonard DM; Shuler KR; Kaltenbronn JS; Quin J; Bur S; Thomas CE; Doherty AM; Scholten JD; Zimmerman KK; Gibbs BS; Gowan RC; Latash MP; Leopold WR; Przybranowski SA; Sebolt-Leopold JS
J Med Chem; 1997 Oct; 40(21):3319-22. PubMed ID: 9341905
[No Abstract] [Full Text] [Related]
17. Natural inhibitors for protein prenyltransferase.
Lee S; Park S; Oh JW; Yang C
Planta Med; 1998 May; 64(4):303-8. PubMed ID: 9619109
[TBL] [Abstract][Full Text] [Related]
18. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R
Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553
[TBL] [Abstract][Full Text] [Related]
19. A cell-based radioligand binding assay for farnesyl: protein transferase inhibitors.
Lobell RB; Davide JP; Kohl NE; Burns HD; Eng WS; Gibson RE
J Biomol Screen; 2003 Aug; 8(4):430-8. PubMed ID: 14567795
[TBL] [Abstract][Full Text] [Related]
20. Farnesyl-derived inhibitors of ras farnesyl transferase.
Kang MS; Stemerick DM; Zwolshen JH; Harry BS; Sunkara PS; Harrison BL
Biochem Biophys Res Commun; 1995 Dec; 217(1):245-9. PubMed ID: 8526918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
